MXPA03009277A - Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata. - Google Patents

Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.

Info

Publication number
MXPA03009277A
MXPA03009277A MXPA03009277A MXPA03009277A MXPA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A
Authority
MX
Mexico
Prior art keywords
health
related quality
life
prostate cancer
adjusted time
Prior art date
Application number
MXPA03009277A
Other languages
English (en)
Inventor
Amitabh Singh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03009277A publication Critical patent/MXPA03009277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se expone en la presente un metodo para modular favorablemente la calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en un paciente que tiene cancer de prostata y un metodo para la medicion del progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud.
MXPA03009277A 2001-04-11 2002-04-11 Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata. MXPA03009277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (1)

Publication Number Publication Date
MXPA03009277A true MXPA03009277A (es) 2004-03-10

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009277A MXPA03009277A (es) 2001-04-11 2002-04-11 Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.

Country Status (10)

Country Link
EP (1) EP1379238A1 (es)
JP (1) JP2005503339A (es)
CN (1) CN1514727A (es)
AR (1) AR033465A1 (es)
BR (1) BR0205970A (es)
CA (1) CA2442591A1 (es)
IL (1) IL158071A0 (es)
MX (1) MXPA03009277A (es)
PE (1) PE20021032A1 (es)
WO (1) WO2002085351A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2652345A1 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea related applications
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Also Published As

Publication number Publication date
PE20021032A1 (es) 2002-11-12
AR033465A1 (es) 2003-12-17
WO2002085351A1 (en) 2002-10-31
BR0205970A (pt) 2003-09-30
IL158071A0 (en) 2004-03-28
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
JP2005503339A (ja) 2005-02-03
CN1514727A (zh) 2004-07-21

Similar Documents

Publication Publication Date Title
WO2004112890A3 (en) Method for intraoperative radiation treatment of breast cancer
GB0128108D0 (en) Therapeutic use
SI1365769T1 (sl) Zdravilo za zdravljenje osteonekroze za oskrbo pacientov pri tveganju razvoja osteonekroze
AU6232099A (en) Method and apparatus for determining autofluorescence of skin tissue
CA2502394A1 (en) Surgical articles
IL161978A0 (en) Method for treating cervical cancer
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
CY1106285T1 (el) Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστου
IL151650A0 (en) Human cord blood as a source of neural tissue for repair of the brain and spinal cord
AU2001297644A1 (en) B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
MY138883A (en) Use of asiatic acid for treatment of cencer
MXPA03009277A (es) Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HK1022651A1 (en) The use of levobupivacaine in facial surgery
GB0020504D0 (en) Therapeutic method
GB0008172D0 (en) Therapy
AU2002257139A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
WO2000031530A3 (en) Screening of nos2 moldulators using p53 miutant cells
UY27257A1 (es) Composición farmacéutica para su uso en la modulación favorable de la calidad de vida relacionada con la salud y progresión temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cáncer de próstata
CN2181304Y (zh) 经口-咽鼓管导管
CN2930621Y (zh) 一种浅尿道镜
AU2002317169A1 (en) Use of the indication of the expression of splice variants of gene 21 for the diagnosis and treatment of tumour diseases